Dave Ricks, CEO of Eli Lilly, speaks within the Oval Workplace throughout an occasion about weight reduction medicine on the White Home in Washington, Nov. 6, 2025.
Andrew Caballero-Reynolds | AFP | Getty Photos
Eli Lilly opposes the White Home’s push to codify “most favored nation” drug pricing into legislation, CEO Dave Ricks mentioned in an interview with CNBC.
Lilly is one in every of greater than a dozen drugmakers that signed offers with the Trump administration final yr agreeing to cost comparable costs for prescribed drugs within the U.S. as in different rich nations. President Donald Trump has lengthy complained that Individuals pay excessive costs to subsidize low costs for drugs in the remainder of the world.
The pharmaceutical business thought the agreements would pacify these issues and thwart makes an attempt to make “most favored nation” pricing the legislation. However the White Home in current months has pushed Congress to codify parts of the offers. The draft textual content hasn’t been shared publicly, although the administration has mentioned it is attempting to get pharmaceutical firms to again the trouble.
Lilly would not assist it, Ricks mentioned.
“Once you throw it into the congressional course of, what goes in isn’t what is going on to return out,” Ricks mentioned. “And I feel we see lots of people who would quite scale back costs right this moment and never fear about whether or not we’ve any new medicines tomorrow, not fear about whether or not America may have a strong drug business and we’ll have the ability to do analysis on this nation. And I fear about these issues, so I do not suppose that is a terrific concept, and we have been fairly clear with the administration and the congressional leaders about that.”
Ricks mentioned he thinks the Trump administration and management on the Hill are listening to the corporate’s issues, however he mentioned Lilly will use “all of the instruments we’ve to fight unhealthy coverage, and we expect it could be unhealthy coverage.”
